The Liposome Company begins orphan drug phase II trials in AIDS patients with MAI.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004337:Drug Carriers; D004341:Drug Evaluation; D006801:Humans; D008081:Liposomes; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000188:drug therapy*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008081:Liposomes; C070363:TLC G 565